Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

FSD Pharma Inc. (C:HUGE)

Business Focus: Bio Therapeutic Drugs

May 11, 2022 06:00 am ET
InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. A Media Snippet accompanying this...
May 10, 2022 03:00 am ET
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce today the closing of the sale of the Company’s former cannabis processing facility located in Cobourg, Ontario, Canada (the “Facility”) for gross proceeds of CAD$16,400,000 in cash.
May 06, 2022 10:41 am ET
FSD Pharma Announces Dismissal of Derivative Complaint
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that the Company was successful in its motion to dismiss the derivative claim that was filed by Mr. Maheep Goyal, a shareholder (the “Plaintiff”) on July 20, 2021 in Delaware against the Company and its directors and officers (the “Claim”). In a decision dated May 5, 2022, the Delaware court dismissed the Claim without prejudice on the grounds that Mr. Maheep Goyal, t
May 02, 2022 03:30 am ET
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that on April 15th, 2022, the Company entered into a contract with Tekkfund Capital Corp (“TCC”) for services to structure and assist with certain business development strategies (the “TCC Agreement”), pursuant to which the Company will (i) pay TCC a monthly fee of C$12,500 plus HST; and (ii) issue, on a monthly basis, 7,000 Class B subordinate voting shar
Apr 21, 2022 08:30 am ET
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company’s Advisory Board.
Apr 08, 2022 08:30 am ET
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today, pursuant to a court endorsement, the cancellation of 504,888 Class B subordinate voting shares previously issued to the Company’s former Chief Executive Officer, Dr. Raza Bokhari. This follows the prior cancellation of 156,278 Class B subordinate voting shares previously issued to certain former directors of the Company.
Apr 06, 2022 08:30 am ET
FSD Pharma Issues Corporate Updates
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the following corporate updates;
Mar 31, 2022 09:30 am ET
FSD Pharma Announces Filing of Year-End 2021 Results
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, audited financial results for the fourth quarter and full year then ended and accompanying management discussion and analysis.
Mar 15, 2022 03:30 am ET
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Crystal Research Associates LLC has released an Executive Informational Overview® (EIO) on FSD Pharma. The 58 page paid report can be found on FSD Pharma’s
Feb 28, 2022 03:10 am ET
InvestmentPitch Media Video Discusses FSD Pharma’s, a Life Sciences Holding Company, Agreement to Sell Former Cannabis Processing Facility in Cobourg, Ontario for $16,500,000 – Video Available on Inve
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has entered into a firm agreement in connection with the sale of its 64.43-acre, former cannabis...
Feb 25, 2022 08:30 am ET
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has entered into a firm agreement in connection with the sale of its former cannabis processing facility (the “Facility”) located in Cobourg, Ontario and the 64.43 acre property on which the facility is located (the “Transaction”). In consideration for the purchase of the Facility, the Purchaser has agreed to pay a cash sum of CAD$16,500,000, including a depo
Jan 20, 2022 03:30 am ET
FSD Pharma Announces Launch of New Corporate Website
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. To view the website, please visit
Jan 18, 2022 03:30 am ET
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, warmly congratulates Eleanor N. Fish, Ph.D., a member of its Research and Clinical Advisory Board, on her appointment to the Order of Canada.
Jan 04, 2022 03:30 am ET
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET on January 10, 2022. To register, please
Dec 30, 2021 03:30 am ET
FSD Pharma Announces Share Repurchase Program
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that its Board of Directors has authorized the repurchase by the Company of up to 2,000,000 of its Subordinate Class B Voting Shares (the “Subordinate Voting Shares”) from time to time over the next 12 months at prevailing market prices in order to allow the Company to use its excess cash reserves to strategically return value to shareholders.
Dec 09, 2021 08:00 am ET
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has formed a Regulatory Advisory Board (“RAB”) and has appointed Joga Gobburu, B.Pharm. (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members.
Dec 03, 2021 08:43 am ET
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and accessible to view on the investor relations section of FSD’s website at
Dec 02, 2021 04:55 pm ET
The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings
VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases.
Dec 02, 2021 08:00 am ET
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it is sharing pre-clinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the Company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS.
Nov 16, 2021 08:30 am ET
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board.
Oct 19, 2021 08:30 am ET
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has entered into an agreement with Covar Pharmaceuticals Inc. (“Covar”), a contract development and manufacturing services organization (“CDMO”), to commence work on providing research quantities of FSD’s drug candidate, Lucid-PSYCH, on an exclusive basis for further clinical evaluation.
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Oct 13, 2021 08:00 am ET
FSD Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
TORONTO, Oct. 13, 2021 /PRNewswire/ -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce that Anthony Durkacz, Interim CEO of FSD Pharma, and Dr. Lakshmi P. Kotra, CEO of FSD's wholly-owned subsidiary Lucid Psycheceuticals, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.
Sep 22, 2021 06:30 pm ET
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has retained the services of Hybrid Financial Ltd. (“Hybrid”), North Equities Corp. (the "North Equities"), Looking Glass Capital Consultants (“Looking Glass”), Worldwide Media Solutions, LLC (“BGTV Direct”), KCSA Strategic Communications ("KCSA"), and Digi Messaging & Advertising (“Digi”), which will each play a key role in assis
Sep 21, 2021 09:47 am ET
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (“Lucid”), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for approximately CAD$11.3 million (US$8.9 million) in FSD Pharma stock (the “
Aug 25, 2021 09:00 am ET
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announces today it...
Aug 25, 2021 09:00 am ET
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announced today it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (“Lucid”), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for approximately US$9 million (CAD$11.3 million) in FSD
Aug 24, 2021 04:01 pm ET
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide ("PEA"), or FSD-201, for use in treating COVID-19.
Jul 27, 2021 08:47 am ET
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) announced today that the board of directors had terminated the employment of the Company’s Chief Executive Officer, Dr. Raza Bokhari for cause.
Jun 03, 2021 09:00 am ET
FSD Pharma Inc. Appoints a New Independent Director
FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) is pleased to announce the appointment of Mr. Adnan Bashir as an independent member of its Board of Directors (the “Board”), upon the recommendation of the Company’s Compensation, Nomination and Governance Committee.
May 26, 2021 06:59 pm ET
KILL FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer
FSD Pharma Inc. requests that their press release NewsItemId: 20210513005614 issued May 13, 2021 “FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer” be removed.
May 17, 2021 03:18 am ET
FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders – Nominees of the Concerned Shareholders Elected to the Board of Directors
FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) is pleased to announce the results of its annual general and special meeting of the shareholders held on May 14th, 2021 (the “Meeting”) at which 54.17% of the votes attached to the issued and outstanding Class B Subordinate Voting Shares (“Class B Shares”) and Class A Multiple Voting Shares (“Class A Shares”) were represented. The board of directors of FSD (the “Board”) was fixed at seven directors. Each of the nominees of the group of concerned shareholders
May 13, 2021 09:00 am ET
FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") announced today that it has filed a criminal complaint with Toronto Police Services, Financial Crimes Unit, against Mr. Donal Carroll, the Company's former chief financial officer. The complaint asserts that Mr. Carroll has intentionally interfered with the Company's banking in order to disrupt FSD’s business in the midst of an ongoing proxy contest, in alleged contravention of criminal law and Mr. Carroll's fiduciary and other duties to the Company.
May 12, 2021 12:49 pm ET
FSD Management and Board Suffers Multiple Court Losses as Shareholder Meeting Approaches
Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - On Monday, May 10, 2021, at the request of Messrs. Anthony Durkacz and Zeeshan Saeed, founding shareholders and members of the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the "Company" or "FSD"), the Ontario Superior Court of Justice (Commercial List) (the "Court") issued an order appointing Ms. Carol Hansell as independent chair of the Company's shareholders' meeting to be held on May 14, 2021 (the "Meeting") and dismissed FSD's application challenging the Concerned Shareholders' information circular.
May 10, 2021 08:30 am ET
FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Animal Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat Gastrointestinal enteropathy in dogs. The application has been accepted for review.
May 05, 2021 04:23 pm ET
FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company’s Nominees to the Board Using Only the BLUE Proxy
FSD Pharma Inc. (the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent international corporate governance analysis and proxy advisory firm, has recommended that shareholders vote FOR all Company Director Nominees (the "Management Director Nominees") in a contested election for the Board of Directors and FOR the elimination of the dual-class share structure (the "Dual-Class Sunset") at the annual and special meeting of shareholders on May 14, 2021 (the "Meeting").
May 05, 2021 08:30 am ET
FSD Pharma Announces Appointment of Interim Chief Financial Officer
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") is pleased to announce the appointment of Nathan Coyle, the Company's Corporate Controller as its Interim Chief Financial Officer, following the departure of Donal Carroll, effective immediately.
May 03, 2021 07:30 am ET
FSD Pharma Issues Important Message to Shareholders and Response to Dissident Circular
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") wishes to alert you to the events that have occurred since the Company filed its Management Information Circular (the "Circular") and the accompanying letter to shareholders related to the Annual & Special Meeting of shareholders scheduled for May 14, 2021, copies of which are available under the Company's SEDAR profile. On April 26, 2021, certain dissident shareholders issued an information circular which included misleading statements and baseless accusations towards the Company's management. In response, the Company is
Apr 26, 2021 09:04 pm ET
Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy
Toronto, Ontario--(Newsfile Corp. - April 26, 2021) - On Monday, April 26, 2021, the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the "Company" or "FSD") filed and mailed an information circular and gold proxy to FSD's shareholders for the upcoming annual general and special meeting of FSD to be held on May 14, 2021 (the "Meeting").
Apr 23, 2021 09:00 am ET
FSD Pharma Files Proxy Materials and Sends Letter to Shareholders
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") announces the filing of its Management Information Circular (the "Circular") and an accompanying letter to shareholders related to the Annual & Special Meeting scheduled for May 14, 2021, copies of which are available under the Company's SEDAR profile.
Apr 05, 2021 07:30 am ET
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting
TORONTO, April 5, 2021 /CNW/ - On Tuesday, March 30, 2021, Anthony Durkacz, a founding director and member of the group of concerned shareholders, which also includes founding shareholder Zeeshan Saeed, (the "Concerned Shareholders") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (the "Company" or "FSD") received a Notice of Appeal from FSD (the "Appeal") of the March 5, 2021 decision (the "Decision") of the Ontario Superior Court of Justice (Commercial List) (the "Court"). The Decision, which resulted from an application to the Court brought by Mr. Durkacz on behalf of the Concern
Mar 31, 2021 05:00 pm ET
FSD Pharma Commences Proceedings Against Dissident Shareholders
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced that it has commenced an application in the Ontario Superior Court seeking orders from the Court about the conduct of FSD’s annual general and special meeting of shareholders currently scheduled for May 14, 2021 (the "Annual Meeting").
Mar 16, 2021 09:56 pm ET
FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces that it has entered into a license agreement (the “License Agreement”) with Innovet Italia S.R.L. (“Innovet”), under which Innovet granted the Company a license to use ultramicronized-palmitoylethanolamide (or ultramicronized PEA) (“ultra-micro PEA”) to develop U.S. Food and Drug Administration (“FDA”) approved veterinary drugs for the treatment of gastro-intestinal diseases in Canine and Feline (Dogs and Cats). In addition, the Company today announces the filing of its year-end results and provides corp
Mar 08, 2021 07:00 am ET
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Iss
Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - The group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) (the "Company" or "FSD") which includes two founding directors, Anthony Durkacz and Zeeshan Saeed, are pleased to announce that they were successful in their request that the Ontario Superior Court of Justice (Commercial List) (the "Court") order the Company to accelerate the date of its previously called annual shareholders' meeting.
Mar 08, 2021 06:00 am ET
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Iss
TORONTO, March 8, 2021 /CNW/ - The group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (the "Company" or "FSD") which includes two founding directors, Anthony Durkacz and Zeeshan Saeed, are pleased to announce that they were successful in their request that the Ontario Superior Court of Justice (Commercial List) (the "Court") order the Company to accelerate the date of its previously called annual shareholders' meeting.
Feb 11, 2021 08:40 am ET
FSD Pharma Announces US$20M At-The-Market Offering
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated February 11, 2021 (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Sales Agent"). Under the Sales Agreement the Company may, at its discretion and from time-to-time during the term of the Sales Agreement, sell, through the Sales Agent, Class B Subordinate Voting Shares of the Company (the "Class B Shares"). Sales of Class B Shares will be made through "at-the-market distributions" as
Jan 26, 2021 07:30 pm ET
FSD Provides Corporate Update
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces the following corporate updates.
Jan 22, 2021 04:30 pm ET
FSD Pharma Sets Date for Annual Meeting
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021.
Dec 15, 2020 08:35 am ET
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) for the treatment of hospitalized patients with COVID-19.
Nov 12, 2020 05:00 pm ET
FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR.
Oct 29, 2020 07:30 am ET
FSD Pharma Announces Settlement of Class Action Proceeding
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that, subject to court certification and other customary conditions, it has entered into a definitive settlement agreement (the "Settlement Agreement") with respect to the class action litigation commenced by a plaintiff shareholder in the Ontario Superior Court of Justice in February 2019 relating to the build-out of its facility in Cobourg, Ontario (the "Settled Action").
Oct 05, 2020 07:30 am ET
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201 COVID-19 Trial”). The company is expected to start dosing patients in October 2020. We believe FSD201 may have the potential to address the over-exuberant inflammatory response characterized by COVID-19 infection tha
Sep 28, 2020 02:30 am ET
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
- FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients
Aug 31, 2020 02:30 am ET
FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201 COVID-19 Trial”). Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. As previously announced, FSD Pharma
Aug 31, 2020 02:30 am ET
FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19
- The study is expected to be conducted at 25-30 hospitals in North America -
Aug 07, 2020 05:45 pm ET
Aug 06, 2020 05:00 pm ET
FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors
TORONTO, ON / ACCESSWIRE / August 6, 2020 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE.CN) ("FSD Pharma" or the "Company") announces the closing of a previously announced agreement with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company ("Shares") and warrants to purchase 1,381,215 Shares (collectively, the "Securities") at a purchase price of US$3.62 per Share in a registered direct offering. Each Share was sold together with one-half of one warrant to purchase a Share. The warrants have an exerc
Aug 06, 2020 05:00 pm ET
FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announces the closing of a previously announced agreement with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 1,381,215 Shares (collectively, the “Securities”) at a purchase price of US$3.62 per Share in a registered direct offering. Each Share was sold together with one-half of one warrant to purchase a Share. The warrants have an exercise price of US$4.26 per Share, are immediately exercisable and expire five years from th
Jul 31, 2020 04:49 pm ET
FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2020) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) CEO and Chairman, Raza Bokhari speaks about the company's lead Compound, PEA, to treat COVID-19.
Jul 31, 2020 09:00 am ET
FSD Pharma Inc. Announces US$10 Million Registered Direct Offering
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 1,381,215 Shares (collectively, the “Securities”) at a purchase price of US$3.62 per Share in a registered direct offering. The warrants will have an exercise price of US$4.26 per Share, will be immediately exercisable and will expire five years from the date of issuance. The closing of the offering is expected
Jul 31, 2020 09:00 am ET
FSD Pharma Inc. Announces US$10 Million Registered Direct Offering
TORONTO, ON / ACCESSWIRE / July 31, 2020 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company"), today announced that it has entered into definitive agreements with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company ("Shares") and warrants to purchase 1,381,215 Shares (collectively, the "Securities") at a purchase price of US$3.62 per Share in a registered direct offering. The warrants will have an exercise price of US$4.26 per Share, will be immediately exercisable and will
Jul 30, 2020 02:30 am ET
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that it has notified Health Canada of the Company’s decision to forfeit the licenses of its wholly-owned subsidiary, FV Pharma, Inc. (“FV Pharma”) and suspend all activities by FV Pharma within 30 days of the notification date. FSD Pharma has begun the process of liquidating all FV Pharma assets, including the sale of the Company’s cannabis production facility in Cobourg, Ontario.
Jul 30, 2020 02:30 am ET
Jul 13, 2020 02:30 am ET
FSD Pharma Announces US$20M At-The-Market Offering
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has entered into an Equity Distribution Agreement dated July 10, 2020 (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”). Under the Sales Agreement the Company may, at its discretion and from time-to-time during the term of the Sales Agreement, sell, through the Sales Agent, Class B Subordinate Voting Shares of the Company (the “Class B Shares”) for aggregate gross proceeds to the Company of up to US$20.0 million (t
Jul 13, 2020 02:30 am ET
FSD Pharma Announces US$20M At-The-Market Offering
TORONTO, CANADA / ACCESSWIRE / July 13, 2020 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated July 10, 2020 (the "Sales Agreement") with A.G.P. / Alliance Global Partners (the "Sales Agent"). Under the Sales Agreement the Company may, at its discretion and from time-to-time during the term of the Sales Agreement, sell, through the Sales Agent, Class B Subordinate Voting Shares of the Company (the "Clas
Jun 22, 2020 02:30 am ET
FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women.
Jun 09, 2020 11:39 am ET
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
TORONTO, June 9, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the "Company") announces the closing of a previously announced private placement of 1,500,000 of the Company's Class B Subordinate Voting Shares ("Shares") at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the "Securities") of the Company to certain institutional investors for gross proceeds, before deducting placement fees and other estimated offering expenses payable by the Company, of approximately C$10.125 million. The warrants have a five-year term and an exerci
Jun 09, 2020 11:30 am ET
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private placement of 1,500,000 of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the ”Securities”) of the Company to certain institutional investors for gross proceeds, before deducting placement fees and other estimated offering expenses payable by the Company, of approximately C$10.125 million. The warrants have a five-year term and an exercise price of C$9.65 per sh
Jun 04, 2020 09:43 am ET
FSD Pharma Inc. Announces C$10.125 Million Private Placement
TORONTO, June 4, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) ("FSD Pharma" or the "Company"), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company's Class B Subordinate Voting Shares ("Shares") at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company. The warrants will have a five year-term and an exercise price
Jun 04, 2020 09:40 am ET
FSD Pharma Inc. Announces C$10.125 Million Private Placement
FSD Pharma Inc. (NASDAQ: HUGE) (“FSD Pharma” or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company. The warrants will have a five year-term and an exercise price of C$9.65 per share. The closing
Jun 03, 2020 09:17 am ET
IIROC Trade Resumption - HUGE
VANCOUVER, BC, June 3, 2020 /CNW/ - Trading resumes in:
Jun 03, 2020 08:57 am ET
IIROC Trading Halt - HUGE
VANCOUVER, BC, June 3, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 03, 2020 02:30 am ET
FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammato
Jun 03, 2020 02:30 am ET
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
TORONTO, June 3, 2020 /CNW/ - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-2
May 21, 2020 08:30 am ET
May 21, 2020 08:30 am ET
FSD Pharma Monetizes Non-Core Asset With Sale of Partial Equity Stake in Pharmadrug Inc.
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) (“FSD Pharma” or the "Company") today announced the sale of 5.0 million common shares of Pharmadrug Inc. (CSE:BUZZ) (formerly Aura Health) in a privately negotiated transaction at C$0.08 per share for cash proceeds of C$400,000. Under the terms of the sale, the buyer has the option through June 26, 2020 to purchase an additional 5.0 million shares of Pharmadrug at C$0.10 per share from FSD Pharma for cash proceeds of C$500,000. Additional transaction details can be found on the SEDI website at
May 14, 2020 05:12 pm ET
Mar 23, 2020 09:17 am ET
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario
TORONTO, March 23, 2020 /CNW/ - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2 pandemic on its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), a licensed producer under Canada's Cannabis Act and Regulations, and its facility in Cobourg, Ontario.  The Company's actions are aligned with evolving guidance from provincial and local Canadian health officials.
Mar 23, 2020 09:13 am ET
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2 pandemic on its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed producer under Canada’s Cannabis Act and Regulations, and its facility in Cobourg, Ontario. The Company’s actions are aligned with evolving guidance from provincial and local Canadian health officials.
Mar 09, 2020 08:30 am ET
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
TORONTO, March 9, 2020 /CNW/ - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of ultra-micronized-PEA in normal healthy volunteers.  
Mar 09, 2020 08:30 am ET
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of ultra-micronized-PEA in normal healthy volunteers.
Mar 04, 2020 02:30 am ET
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that Executive Co-Chairman and CEO, Raza Bokhari, MD will be joined by the Company’s founders, Anthony Durkacz and Zeeshan Saeed, members of its Board of Directors, and leadership team to ring the opening bell at the Canadian Securities Exchange (CSE) on Friday, March 6, 2020 at 9:30 a.m. Eastern time.
Mar 04, 2020 01:30 am ET
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020
– Reports audited financial results for the Fourth Quarter and Full Year ended December 31, 2019 –
Feb 20, 2020 02:30 am ET
FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced the sale of its 12% equity interest in Cannara Biotech Inc. (CSE: LOVE) ("Cannara") to a consortium of buyers for cash proceeds of more than $7.7 million (the "Share Sale Transaction").
Feb 20, 2020 01:30 am ET
FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech
TORONTO, Feb. 20, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced the sale of its 12% equity interest in Cannara Biotech Inc. (CSE: LOVE) ("Cannara") to a consortium of buyers for cash proceeds of more than $7.7 million (the "Share Sale Transaction").
Feb 11, 2020 09:30 am ET
FSD Pharma CEO, Dr. Raza Bokhari, Discusses 2020 Goals with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 11, 2020) - The Stock Day Podcast welcomed FSD Pharma (NASDAQ: HUGE) (the Company"), a specialty biotech pharmaceutical R&D company focused on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. CEO of the Company, Dr. Raza Bokhari, joined Stock Day host Everett Jolly.
Feb 05, 2020 02:30 am ET
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD Pharma Biosciences leadership, will be participating in the 22nd Annual BIO CEO & Investor conference, including presenting a company overview at 9:45 a.m. ET on Monday, February 10, 2020.
Feb 05, 2020 01:30 am ET
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
TORONTO, Feb. 5, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD Pharma Biosciences leadership, will be participating in the 22nd Annual BIO CEO & Investor conference, including presenting a company overview at 9:45 a.m. ET on Monday, February 10, 2020.
Feb 04, 2020 02:30 am ET
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”) (collectively, the “Parties”), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement (the “Research Agreement”) designed to accelerate progress of the research project that Solarvest is carrying out (the “CBD Research Project”). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subor
Feb 04, 2020 01:30 am ET
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
TORONTO, Feb. 4, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)  ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V: SVS) ("Solarvest") (collectively, the "Parties"), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement  (the "Research Agreement") designed to accelerate progress of the research project that Solarvest is carrying out (the "CBD Research Project"). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subord
Jan 22, 2020 02:30 am ET
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma’s Scientific Advisory Board (SAB).
Jan 22, 2020 01:30 am ET
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
TORONTO, Jan. 22, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma's Scientific Advisory Board (SAB). 
Jan 17, 2020 02:30 am ET
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the "Company") is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of the Company’s Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET.
Jan 17, 2020 01:30 am ET
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
TORONTO, Jan. 17, 2020 /CNW/ - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company") is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of the Company's Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET.
Jan 09, 2020 01:22 pm ET
INSERTING and REPLACING FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’
Insert in second paragraph, first sentence of release: Executive Co-Chairman and CEO.
Jan 09, 2020 02:30 am ET
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the "Company") announced that its Class B Subordinate Voting Shares (the “Shares”) will commence trading on the Nasdaq Capital Market under the symbol ‘HUGE’ today, January 9, 2020. The Company’s Class B Subordinate Voting Shares will continue to trade on the Canadian Securities Exchange under the symbol ‘HUGE’.
Jan 09, 2020 01:30 am ET
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'
- Management to Present at Biotech Showcase 2020 -
Jan 06, 2020 08:30 am ET
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the "Company") today announced that its Class B Subordinate Voting Shares (the “Shares”) have been approved for listing on the NASDAQ Capital Market (“NASDAQ”) under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020.
Jan 06, 2020 07:30 am ET
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020
TORONTO, Jan. 6, 2020 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced that its Class B Subordinate Voting Shares (the "Shares") have been approved for listing on the NASDAQ Capital Market ("NASDAQ") under the symbol 'HUGE'. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020.
Jan 02, 2020 07:30 am ET
FSD Pharma Strengthens Management Team
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the "Company") today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer. Mr. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD Pharma’s BioSciences Division; and Shahzad Shah, Chief Operating Officer of FV Pharma.
Jan 02, 2020 06:30 am ET
FSD Pharma Strengthens Management Team
- Donal Carroll Appointed Chief Financial Officer, Dr. Sandra Lottes as Vice President and Head of Clinical Research at BioSciences Division, and Shahzad Shah as Chief Operating Officer at FV Pharma -
Dec 16, 2019 08:09 am ET
IIROC Trade Resumption - HUGE
VANCOUVER, Dec. 16, 2019 /CNW/ - Trading resumes in:
Dec 16, 2019 03:30 am ET
FSD Pharma Receives Approval to List Its Shares on Nasdaq
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the "Company") announces that Nasdaq has approved its application to have its Class B Subordinate Voting Shares (the “Shares”) listed on the Nasdaq Capital Market (“Nasdaq”). FSD Pharma expects the Shares to commence trading on Nasdaq in the near future.
Dec 16, 2019 02:30 am ET
FSD Pharma Receives Approval to List its Shares on Nasdaq
TORONTO, Dec. 16, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Nasdaq has approved its application to have its Class B Subordinate Voting Shares (the "Shares") listed on the Nasdaq Capital Market ("Nasdaq"). FSD Pharma expects the Shares to commence trading on Nasdaq in the near future.
Dec 13, 2019 12:37 pm ET
IIROC Trading Halt - HUGE
VANCOUVER, Dec. 13, 2019 /CNW/ - The following issues have been halted by IIROC:
Dec 13, 2019 07:30 am ET
FSD Pharma to Present at Investor Summit on December 17
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, will present an overview of the Company at the Investor Summit conference at 2:35 p.m. ET on Tuesday, December 17, 2019 at the Kimpton Hotel Monaco in Philadelphia.
Dec 13, 2019 06:30 am ET
FSD Pharma to Present at Investor Summit on December 17
TORONTO, Dec. 13, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, will present an overview of the Company at the Investor Summit conference at 2:35 p.m. ET on Tuesday, December 17, 2019 at the Kimpton Hotel Monaco in Philadelphia.
Dec 05, 2019 07:30 am ET
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.
Dec 05, 2019 06:30 am ET
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11
TORONTO, Dec. 5, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.
Nov 29, 2019 04:30 pm ET
FSD Pharma Reports Third Quarter 2019 Financial Results
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today reported financial and operational results for the three and nine months ended September 30, 2019. These filings are available for review on the Company’s SEDAR profile at www.sedar.com.
Nov 29, 2019 03:30 pm ET
FSD Pharma Reports Third Quarter 2019 Financial Results
- Announces intent to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20 –
Nov 29, 2019 11:50 am ET
Morganti & Co., P.C. - Shareholders Target FSD Pharma Corp
Morganti & Co., P.C., a cross border shareholder’s rights law firm, confirms that it has commenced a shareholder class action lawsuit against FSD Pharma Inc. (TSX: “HUGE").
Nov 05, 2019 01:33 pm ET
Canadian Securities Exchange Attracts First Israeli Company Listings
IM Cannabis becomes third Israeli cannabis listing in past six weeks
Nov 04, 2019 01:30 am ET
FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Oct 23, 2019 06:00 pm ET
FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018
TORONTO, Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the "Amended 2018 MD&A") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission ("OSC") of the Company's disclosure record.
Oct 22, 2019 09:00 am ET
InvestmentPitch Media Feature Video Discusses FSD Pharma and a Recent Commentary by CEO Raza Bokhari, MD - Video is Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2019) - Today's feature company is FSD Pharma Inc. (CSE:HUGE) (FSE:0K9) (OTCQB:FSDDD), which is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.
Oct 18, 2019 09:00 am ET
InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of Directors - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDD) announced that its Class B shares, which trade on the OTCQB, will have a new symbol FSDDD for a period of 20 business days until November 13th, at which time the symbol will revert back to FSDDF. The temporary change is protocol for stocks that trade on US exchanges that undergo structural events, such as the recent share consolidation of one new share for each 201 old shares, announced by FSD Pharma on October 11th, in order to advance the company's strategic plan to increase visibility among U.S. investors and list on a major U.S. exchange.
Oct 17, 2019 08:30 am ET
FSD Pharma Announces Temporary Change in OTCQB Ticker Symbol to FSDDD
TORONTO, Oct. 17, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDD) (FRA: 0K9) ("FSD" or the "Company") today announced that the Company's Class B Shares are trading on the OTCQB under the ticker symbol FSDDD for 20 business days, effective as of October 16, 2019. On November 13, 2019, the OTCQB symbol will revert to FSDDF.
Oct 17, 2019 08:30 am ET
FSD Pharma Announces Temporary Change in OTCQB Ticker Symbol to FSDDD
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDD) (FRA: 0K9) (“FSD” or the “Company”) today announced that the Company’s Class B Shares are trading on the OTCQB under the ticker symbol FSDDD for 20 business days, effective as of October 16, 2019. On November 13, 2019, the OTCQB symbol will revert to FSDDF.
Oct 11, 2019 07:30 am ET
FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation
TORONTO, Oct. 11, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") today announced the appointment of former U.S. congressman Stephen Buyer to the Company's Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subordinate voting shares ("Class B Shares" and collectively with the Class A Shares, the "FSD Shares"), each on a 1 to 201 basis (the "Consolidation").
Oct 11, 2019 07:30 am ET
FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") today announced the appointment of former U.S. congressman Stephen Buyer to the Company’s Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subordinate voting shares ("Class B Shares" and collectively with the Class A Shares, the "FSD Shares"), each on a 1 to 201 basis (the "Consolidation").
Oct 01, 2019 08:30 am ET
FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering
TORONTO, Oct. 1, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") is pleased to provide an update on its previously announced private placement of its class B subordinate voting shares ("Shares") at a price of CAD$0.10 per Share (the "Private Placement").  On September 30, 2019, the Company closed an initial tranche of the Private Placement, raising gross proceeds of CAD $4,583,085 from investors, including members of senior management and board of directors, and issuing an aggregate of 45,830,850 Shares. The Shares issued to purchasers in Canada wi
Oct 01, 2019 08:30 am ET
FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") is pleased to provide an update on its previously announced private placement of its class B subordinate voting shares (“Shares”) at a price of CAD$0.10 per Share (the “Private Placement”). On September 30, 2019, the Company closed an initial tranche of the Private Placement, raising gross proceeds of CAD $4,583,085 from investors, including members of senior management and board of directors, and issuing an aggregate of 45,830,850 Shares. The Shares issued to purchasers in Canada
Sep 26, 2019 09:00 am ET
InvestmentPitch Media Video Discusses FSD Pharma's LOI with World Class Extractions Creating JV to Build and Operate Cannabis Extraction/Processing Facility in Cobourg, Ontario - Video Available on In
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), through its wholly-owned subsidiary FV Pharma, has signed a letter of intent with World Class Extractions (CSE: PUMP) (FSE: WCF) to create a joint venture to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario. FSD Pharma and World Class Extractions will each hold a 50% interest in the new joint venture, with each company nominating 2 of the 5 directors, with the 5th director being independent.
Sep 25, 2019 07:30 am ET
FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center
-  Joint Venture to develop, manage and operate cannabis extraction and processing center at FSD Pharma Facility in Cobourg, Ontario -
Sep 25, 2019 07:30 am ET
FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma”, “FSD” or “the Company”) today announced the signing of a letter of intent (“LOI”) to establish a joint venture (the “Joint Venture”) with the Company’s wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), and World-Class Extractions Inc. (“World-Class”) (CSE: PUMP) (FRA: WCF) to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario (the “Facility”) to extract various cannabidiol and other valuable elements from cannabis and hemp plants.
Aug 30, 2019 12:01 am ET
FSD Pharma Announces Private Placement
Also Reports Q2 2019 Financial Results
Aug 30, 2019 12:01 am ET
FSD Pharma Announces Private Placement
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") is pleased to announce that the Company has launched a private placement of up to US$5 million of its class B subordinate voting shares (“Shares”) at a price of C$0.10 per Share without any warrant coverage (the “Private Placement”). The Company expects to close the Private Placement by September 30, 2019. To date, C$1,314,000 million of proceeds have been committed and received. The CEO has personally invested US$500,000 and the FSD Pharma leadership team, representing founders, directors and members of the senior
Aug 21, 2019 07:30 am ET
FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment
Orders for medicinal cannabis can be placed on fvpharma.com
Aug 21, 2019 07:30 am ET
FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) today announced the launch of its online ordering system for the direct fulfillment of medicinal cannabis orders. Through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), clients with a prescription from a medical practitioner or a registration number with Health Canada can now place an order online for dried cannabis on
Aug 13, 2019 08:23 am ET
Aura Announces Pharmadrug Operational & Investor Relations Update
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the “German Business” or “Pharmadrug”) and additional resources allocated to investor relations....
Jul 30, 2019 07:30 am ET
FSD Pharma Appoints Larry Kaiser, MD, FACS, Dean, Lewis Katz School of Medicine at Temple University as Chairman of Its Scientific Advisory Board
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) today announced the appointment of Larry Kaiser, MD, FACS, Dean, Lewis Katz School of Medicine at Temple University and President & CEO of Temple Health System as Chairman of its Scientific Advisory Board (SAB). Dr. Kaiser replaces Dr. Charles Pollack, who has been placed on leave of absence. The Company also announced the appointment of Adam Friedman, MD, FAAD, Ken Mackie, MD and Sara Jane Ward, PhD to its SAB, three renowned cannabis researchers and scientists who bring the total SAB membership to nine.
Jul 26, 2019 07:45 am ET
Leo Acquisitions and CBx Brands Announce Letter of Intent for Proposed Qualifying Transaction
Leo Acquisitions Corp. (NEX: LEQ.H) (“Leo” or the “Company”) and CBx Brands Inc. (“CBx”) are pleased to announce that they have entered into a letter of intent (the “LOI”), dated July 10, 2019, pursuant to which the Company and CBx have agreed to...
Jul 02, 2019 07:30 am ET
FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals
FSD acquires platform company to advance R&D of targeted application of micro-Palmitoylethanolamide impacting the human endocannabinoid system
Jul 02, 2019 07:30 am ET
FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company (the “Parties”), announced today that, on June 28, 2019, they finalized the acquisition by FSD Pharma of all of the issued and outstanding securities of Prismic (the "Transaction"). Pursuant to the terms of a previously-announced securities exchange Agreement, FSD Pharma has acquired all outstanding common and preferred shares of Prismic for an aggregate purchase price of approximately US$17.5 million (CAD$23.4 milli
Jun 24, 2019 07:30 am ET
FSD Pharma Receives Full "Sale for Medical Purposes" Cannabis License from Health Canada
-Full license allows FSD to deliver cannabis to medicinal use markets-
Jun 24, 2019 07:30 am ET
FSD Pharma Receives Full “Sale for Medical Purposes” Cannabis License from Health Canada
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”) has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license is effective as of June 21, 2019.
Jun 14, 2019 08:15 am ET
FSD Pharma Continues to Add Expert Advisors Amid Buildout of Massive Facility -- CFN Media
Seattle, Washington--(Newsfile Corp. - June 14, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company has been focused on building out its board of directors and advisory board since becoming a full Canadian licensed producer earlier this year. After receiving its cultivation license in 2017, the company began work on a massive cultivation facility that could house nearly four million sq. ft. on 70 acres of land before receiving its sales license in April of this year.
Jun 12, 2019 07:30 am ET
FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors
TORONTO, June 12, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company's Board of Directors.
Jun 12, 2019 07:30 am ET
FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company’s Board of Directors.
Jun 06, 2019 07:30 am ET
FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board
– Ziva Cooper, Ph.D. and Mallory Loflin, Ph.D. become latest members of the renowned group of FSD Scientific Advisors led by Charles Pollack, Jr. MD, FACEP
Jun 06, 2019 07:30 am ET
FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), is pleased to announce the addition of two distinguished cannabis researchers to the company’s Scientific Advisory Board (“SAB”).
Jun 05, 2019 08:46 am ET
Aura Provides Update on Pharmadrug and Its European Strategy
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to provide an update on its operations and corporate strategy regarding the German medical cannabis market. As announced on May 17, 2019, the Company closed its acquisition of 80% of...
Jun 04, 2019 07:30 am ET
FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division -- CFN Media
Seattle, Washington--(Newsfile Corp. - June 4, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company may be known for having one of the largest cultivation footprints in the world with nearly 70 acres and four million square feet, but it's equally focused on advancing the science behind both its cultivation methods and products. After its acquisition of Prismic Biosciences, the company has doubled down on developing cannabinoid-based pharmaceuticals targeting various conditions.
Jun 03, 2019 08:30 am ET
Jun 03, 2019 08:30 am ET
Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that Executive Co-Chairman and Chief Executive Officer, Dr. Raza Bokhari, will be featured in the 2019 BIO International Convention’s panel presentation, “Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots,” on June 4 in Philadelphia, PA.
Jun 03, 2019 07:30 am ET
FSD Pharma Names Raza Bokhari, M.D. as Permanent CEO
Company Also Reports Q1 2019 Financial Results
Jun 03, 2019 07:30 am ET
FSD Pharma Names Raza Bokhari, M.D. as Permanent CEO
The Board of Directors of FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), unanimously voted Raza Bokhari, M.D., Executive Co-Chairman of the Board, as permanent Chief Executive Officer. Dr. Bokhari has served as interim CEO of the Company since February.
May 31, 2019 07:30 am ET
FSD Pharma Congratulates High Tide on the Resumption of Retail Cannabis Licensing by AGLC in Alberta
TORONTO, May 31, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") would like to congratulate High Tide Inc. (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) ("High Tide") on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products.
May 31, 2019 07:30 am ET
FSD Pharma Congratulates High Tide on the Resumption of Retail Cannabis Licensing by AGLC in Alberta
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) would like to congratulate High Tide Inc. (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) (“High Tide”) on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products.
May 28, 2019 07:30 am ET
Edward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division
TORONTO, May 28, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr., M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years' experience in leadership roles at major pharmaceutical companies and clinical research organizations.
May 28, 2019 07:30 am ET
Edward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr., M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years’ experience in leadership roles at major pharmaceutical companies and clinical research organizations.
May 20, 2019 03:00 am ET
FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board
Daniele Piomelli, Ph.D., Ryan Vandrey, Ph.D. and David Casarett, MD, MA Join distinguished group of Scientific Advisors
May 20, 2019 03:00 am ET
FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), is pleased to announce that three eminent cannabis researchers have joined the company’s Scientific Advisory Board (“SAB”).
May 10, 2019 07:30 am ET
FSD Pharma CEO Lays Out Roadmap in Exclusive Interview with CFN Media
Seattle, Washigton--(Newsfile Corp. - May 10, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSSDF). The company is a licensed producer focused on building out a 3.9 million sq. ft. indoor hydroponic facility near Toronto capable of producing 400,000 kilograms of dried cannabis per year. With a newly acquired sales license and 25,000 sq. ft. already in production, the company is on the cusp of generating revenue through partnerships with its tenants where it's entitled to royalty income on production.
May 08, 2019 07:30 am ET
FSD Pharma Investments Pay Off Amid Robust Expansion at Ontario Facility -- CFN Media
Seattle, Washington--(Newsfile Corp. - May 8, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSSDF). The company reported its fourth quarter financial results following a major year of accomplishments. Based in Cobourg, Ontario, the company's massive former Kraft Foods facility sits on 72 acres of land with nearly four million sq. ft. of expansion capacity. Management projects that the facility could generate upwards of 400 million grams of dried cannabis flower per year at full capacity.
May 07, 2019 07:00 am ET
May 07, 2019 07:00 am ET
FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or “FSD”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement. Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma and Solarvest have made investments into one another and
May 06, 2019 07:00 am ET
FSD Pharma Reports 2018 Year-End Results
TORONTO, May 6, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) ("FSD Pharma", "FSD" or "the Company") today reported its financial and operational results for the fourth quarter and fiscal year-ended December 31, 2018. These filings are available for review on the Company's SEDAR profile at www.sedar.com.
May 06, 2019 07:00 am ET
FSD Pharma Reports 2018 Year-End Results
FSD Pharma Inc. (CSE:HUGE) (OTC:FSDDF) (FRA:0K9) (“FSD Pharma”, “FSD” or “the Company”) today reported its financial and operational results for the fourth quarter and fiscal year-ended December 31, 2018. These filings are available for review on the Company’s SEDAR profile at www.sedar.com.
May 02, 2019 11:51 am ET
FSD Pharma provides update on status of 2018 year-end filings
TORONTO, May 2, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) ("FSD Pharma" or "FSD") announces this morning that it has been delayed in filing its audited annual financial statements for the period ending December 31, 2018, the related management's discussion and analysis and the certificates of its CEO and CFO (collectively the "Required Filings") with Canadian securities regulators. 
May 02, 2019 11:36 am ET
FSD Pharma Provides Update on Status of 2018 Year-End Filings
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or “FSD”) announces this morning that it has been delayed in filing its audited annual financial statements for the period ending December 31, 2018, the related management’s discussion and analysis and the certificates of its CEO and CFO (collectively the “Required Filings”) with Canadian securities regulators.
May 01, 2019 08:00 am ET
FSD Pharma Doubles Down on Endocannabinoid-based Pain Management -- CFN Media
Seattle, Washington--(Newsfile Corp. - May 1, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FSE: 0K9). The company has already staked out its plans to address this crisis through endocannabinoid-based treatment options. After partnering with SciCann Therapeutics, the company recently announced the planned acquisition of a specialty pharmaceutical company focused on the space.
Apr 26, 2019 01:30 pm ET
FSD Pharma and MP Kim Rudd Host Media Event at Cobourg Production Facility
TORONTO, April 26, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that in celebration of its wholly-owned subsidiary FV Pharma Inc. having been awarded a sales license by Health Canada, the company is hosting a media event at its headquarters in Cobourg at 520 William St., a former Kraft plant. Presenting at the event are the Company's senior management team members, local MP, Kim Rudd and Cobourg Mayor, John Henderson.
Apr 26, 2019 01:30 pm ET
FSD Pharma and MP Kim Rudd Host Media Event at Cobourg Production Facility
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that in celebration of its wholly-owned subsidiary FV Pharma Inc. having been awarded a sales license by Health Canada, the company is hosting a media event at its headquarters in Cobourg at 520 William St., a former Kraft plant. Presenting at the event are the Company’s senior management team members, local MP, Kim Rudd and Cobourg Mayor, John Henderson.
Apr 24, 2019 03:00 am ET
FSD Pharma Announces Share Exchange Transaction with Aura Health
- Intended Transaction positions FSD to establish distribution channel in Germany & Eurozone -  
Apr 24, 2019 03:00 am ET
FSD Pharma Announces Share Exchange Transaction with Aura Health
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that it has entered into a share exchange transaction with Aura Health Inc. (“Aura”). Pursuant to the agreement, FSD acquired 13,562,386 Aura shares valued at $3 million issued from treasury in exchange for 13,181,019 FSD shares issued from treasury valued at $3 million. Aura Health is a Toronto-based cannabis company building an international network of vertically integrated businesses in the medical cannabis industry.
Apr 23, 2019 09:10 am ET
InvestmentPitch Media Video Discusses FSD Pharma and its New Additional License to Sell Cannabis for Medical Purposes - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF) announced that its wholly-owned subsidiary FV Pharma, currently a licensed cannabis producer, has received its "Sale for Medical Purposes" license under the Cannabis Act in Canada. This additional license permits the current FSD facility to supply and sell cannabis products, with management anticipating an amended sales license in the near future to include the sale of dried and fresh cannabis flower.
Apr 23, 2019 07:30 am ET
FSD Pharma Secures Sales License for Massive Production Facility -- CFN Media
Seattle, Washington--(Newsfile Corp. - April 23, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9). The company became the latest licensed producer to possess both cultivation and sales licenses on April 22 after securing its cannabis sales license from Health Canada. With nearly four million sq. ft. of space in a former Kraft Foods plant in Cobourg, Ontario, the company is uniquely positioned to scale up and become one of the largest licensed producers in the country over the coming quarters.
Apr 23, 2019 03:00 am ET
FSD Pharma to Acquire Prismic Pharmaceuticals
This transaction positions FSD to help contribute to addressing the opioid crisis through use of synthetic cannabinoids 
Apr 23, 2019 03:00 am ET
FSD Pharma to Acquire Prismic Pharmaceuticals
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic (the “Transaction”). Prismic is developing novel non-addictive prescription drugs with unique safety profiles with the goal of addressing the opioid crisis bas
Apr 22, 2019 08:30 am ET
FSD Pharma Receives Cannabis Sales License from Health Canada
- New license positions FSD to serve the growing medicinal use markets -
Apr 22, 2019 03:00 am ET
FSD Pharma Receives Cannabis Sales License from Health Canada
- New license positions FSD to serve the growing medicinal use markets -
Apr 22, 2019 03:00 am ET
FSD Pharma Receives Cannabis Sales License from Health Canada
FSD Pharma Inc. (CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019.
Apr 17, 2019 10:08 am ET
FSD Pharma to Present at Arcview Investor Forum
- Participate in panel presentations on a variety of issues affecting the industry -
Apr 17, 2019 09:39 am ET
FSD Pharma to Present at Arcview Investor Forum
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that Dr. Raza Bokhari, Co-Chairman and Chief Executive Officer of FSD Pharma will participate in the Arcview Investor Forum being held April 23-25, 2019, in Vancouver. The event will feature leading public and private companies and thought leaders who are shaping the future of the industry.
Apr 12, 2019 10:15 pm ET
FSD Pharma, Experienced CEO Has Brought Good Returns for Investors, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - April 12, 2019) - New CEO Raza Bokhari discusses exciting partnerships with Canntab and World Class Extraction.
Apr 11, 2019 07:00 am ET
FSD Pharma Explores Insurance Coverage for Medical Cannabis in Canada -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FFT: 0K9)....
Apr 10, 2019 10:00 am ET
Cannabis Sticks to its Roots: Cannabis Companies Continue to Prioritize the Importance of “People”
Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot looking at how, as the sector matures, companies are racing to snap up industry leaders to enhance their position in the marketplace....
Apr 04, 2019 07:30 am ET
FSD Pharma Appoints Charles Pollack Jr. MD, FACEP as Chairman of the Scientific Advisory Board
TORONTO, April 4, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today the appointment of Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP, as Chairman of its Scientific Advisory Board ("SAB"). In this capacity Dr. Pollack will serve as a strategic guide and resource to the Company as it develops disruptive, science-based, cannabinoid therapeutics.
Apr 04, 2019 07:30 am ET
FSD Pharma Appoints Charles Pollack Jr. MD, FACEP as Chairman of the Scientific Advisory Board
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today the appointment of Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP, as Chairman of its Scientific Advisory Board (“SAB”). In this capacity Dr. Pollack will serve as a strategic guide and resource to the Company as it develops disruptive, science-based, cannabinoid therapeutics.
Mar 28, 2019 07:30 am ET
 FSD Pharma to Establish Presence in Canada’s Insurance Regimes
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today the signing of a consulting agreement with Joseph L. Romano, a well-respected lawyer with a strong track-record in personal injury law. Mr. Romano has been working with medical cannabis since 2006, assisting people coping with chronic pain to have access to medical cannabis, a viable alternative to opioid based medications.
Mar 28, 2019 07:30 am ET
FSD Pharma to Establish Presence in Canada's Insurance Regimes
- Signs agreement focusing on exploring insurance coverage for medical cannabis Canada wide -
Mar 21, 2019 08:00 am ET
The SunnySide of Cannabis; Cannabis Growth Boosts Solar Market
Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases the first article in a two part series on how the growing global cannabis market is boosting ancillary markets, including the solar/cleantech industry....
Mar 13, 2019 07:30 am ET
FSD Pharma Announces New Leadership Appointment and Board Change
Dr. Sara May has been appointed as President of FV Pharma
Mar 13, 2019 07:30 am ET
FSD Pharma Announces New Leadership Appointment and Board Change
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), a licensed producer under the Cannabis Act, today announced that Sara May, Ph.D., has been appointed President of FV Pharma (“FV”), a wholly owned subsidiary of FSD Pharma, effective immediately. Dr. May replaces Thomas Fairfull, former President of FV Pharma, as Mr. Fairfull transitions out of the company.
Mar 05, 2019 07:30 am ET
FSD Pharma's Investments Provide Unique Diversification -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9)....
Feb 28, 2019 07:30 am ET
FSD Pharma Enters into Five Year Supply and Loan Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), a licensed producer under the Cannabis Act, announced today that it has entered into a supply and loan agreement (the “Agreement”) with Canntab Therapeutics Ltd. (“Canntab”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD$ 5.0 million of the Supplier’s hemp crop f
Feb 28, 2019 06:30 am ET
FSD Pharma Enters into Five Year Supply and Loan Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal
- FSD enters into agreement for right/ option to purchase up to CAD$ 5 million of hemp crop for 5 years commencing in 2019 -
Feb 27, 2019 08:00 am ET
Cannabis and Cleantech; The Green, Clean Machine of The Future
Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot looking at the growing interest in renewable energy and sustainable practices within the cannabis industry, sparked largely by high demand,...
Feb 26, 2019 07:30 am ET
FSD Pharma's Investments in Cutting-Edge Tech Could Pay Big Dividends -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA:...
Feb 19, 2019 03:00 am ET
FSD Pharma Receives Standard Processing License
FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) announced today that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has received its Standard Processing License (the “Processing License”). According to Health Canada’s new Cannabis Act regulations, the Processing License is required for any facility that is processing more than the equivalent of 600 kg of dried flowers per year.
Feb 19, 2019 02:00 am ET
FSD Pharma Receives Standard Processing License
TORONTO, Feb. 19, 2019 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) announced today that its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), a licensed cannabis producer under the Cannabis Act, has received its Standard Processing License (the "Processing License"). According to Health Canada's new Cannabis Act regulations, the Processing License is required for any facility that is processing more than the equivalent of 600 kg of dried flowers per year.
Feb 14, 2019 07:30 am ET
FSD Pharma Provides Update on Operations, Strategy and Leadership
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD”), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes.
Feb 14, 2019 06:30 am ET
FSD Pharma Provides Update on Operations, Strategy and Leadership
TORONTO, Feb. 14, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD"), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes.
Feb 13, 2019 07:47 pm ET
CBD Med Research and World Class Extractions Announce Signing of Definitive Agreement
CBD Med Research Corp. (“CBD”) and World Class Extractions Inc. (“World Class”) are pleased to announce, further to the parties’ press release dated August 15, 2018, the execution of a definitive business combination agreement (the “Combination...
Feb 12, 2019 07:30 am ET
FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal
FSD Pharma Inc. (CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) (“FSD”), a licensed producer under the Cannabis Act, announced today that it has entered into a supply agreement (the “Agreement”) with Canntab Therapeutics Ltd. (“Canntab”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the fl
Feb 12, 2019 06:30 am ET
FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal
- FSD enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop -
Feb 08, 2019 07:30 am ET
FSD Pharma Responds to and Corrects Misleading Auxly Claims
FSD Pharma Inc.(CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) a licensed producer under the Cannabis Act, responded today to a press release by its former partner, Auxly Cannabis Group Inc. (“Auxly”) to correct misleading claims.